» Articles » PMID: 30104866

A Pathogenic P.His169Asn Mutation Associated with Early-onset Alzheimer's Disease

Overview
Publisher Dove Medical Press
Specialty Geriatrics
Date 2018 Aug 15
PMID 30104866
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Autosomal dominant early-onset Alzheimer's disease (EOAD) is genetically heterogeneous and has been associated with mutations in 3 different genes, coding for amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2). Most frequent cases are associated with mutations in the gene, whereas mutations in the and genes are rare.

Methods: Patient who presented progressive memory decline in her 50s was enrolled in this study. A broad battery of neuropsychological tests and neuroimaging was applied to make the diagnosis. Genetic tests were performed in the patient to evaluate possible mutations using next-generation sequencing (NGS). The pathogenic nature of missense mutation and its 3D protein structure prediction were performed by in silico prediction programs.

Results: A pathogenic mutation in the PSEN2 gene in a Korean patient associated with EOAD was identified. Targeted Next-generation sequencing and Sanger sequencing revealed a heterozygous C to A transition at position 505 (c.505C>A), resulting in a probably missense mutation at codon 169 (p.His169Asn) in PSEN2. PolyPhen-2 and SIFT software analyses predicted this mutation to be a probable damaging variant. This hypothesis was supported by the results of 3D in silico modelling analyses that predicted the p.His169Asn may result in major helix torsion due to histidine to asparagine substitution. Mutation may cause additional stresses with hydrophobic residues on the surface that interact inside the transmembrane domain III, which is a conserved domain in PSEN2 His169.

Conclusion: These findings revealed that the p.His169Asn might be an important residue in PSEN2, which may alter the functions of PSEN2, suggesting its potential involvement with AD phenotype. Future functional studies are needed to evaluate the role of PSEN2 p.His169Asn mutation in AD disease progression.

Citing Articles

A scoping review of the unique landscape and challenges associated with dementia in the Western Pacific region.

Devenney E, Anh N Nguyen Q, Tse N, Kiernan M, Tan R Lancet Reg Health West Pac. 2024; 50:101192.

PMID: 39399870 PMC: 11471059. DOI: 10.1016/j.lanwpc.2024.101192.


Double Mutations in a Patient with Early-Onset Alzheimer's Disease in Korea: An Val551Met and a His169Asn.

Bae H, Shim K, Yoo J, Yang Y, An S, Kang M Int J Mol Sci. 2023; 24(8).

PMID: 37108607 PMC: 10140908. DOI: 10.3390/ijms24087446.


Clinical and genetic characteristics in a central-southern Chinese cohort of early-onset Alzheimer's disease.

Liang Z, Wu Y, Li C, Liu Z Front Neurol. 2023; 14:1119326.

PMID: 37051054 PMC: 10084792. DOI: 10.3389/fneur.2023.1119326.


Cognitive- and memory-enhancing effects of Augmentin in Alzheimer's rats through regulation of gene expression and neuronal cell apoptosis.

Kandeel M, Morsy M, Abd El-Lateef H, Marzok M, El-Beltagi H, Al Khodair K Front Pharmacol. 2023; 14:1154607.

PMID: 36969860 PMC: 10033694. DOI: 10.3389/fphar.2023.1154607.


PSEN2 Thr421Met Mutation in a Patient with Early Onset Alzheimer's Disease.

Yang Y, Bagyinszky E, An S, Kim S Int J Mol Sci. 2022; 23(21).

PMID: 36362122 PMC: 9656741. DOI: 10.3390/ijms232113331.


References
1.
Finckh U, Alberici A, Antoniazzi M, Benussi L, Fedi V, Giannini C . Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology. 2000; 54(10):2006-8. DOI: 10.1212/wnl.54.10.2006. View

2.
Cai Y, An S, Kim S . Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders. Clin Interv Aging. 2015; 10:1163-72. PMC: 4507455. DOI: 10.2147/CIA.S85808. View

3.
Satoh K, Abe-Dohmae S, Yokoyama S, St George-Hyslop P, Fraser P . ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. J Biol Chem. 2015; 290(40):24152-65. PMC: 4591804. DOI: 10.1074/jbc.M115.655076. View

4.
Xia M, Chen S, Shi Y, Huang Y, Xu J, Zhao T . Probable novel PSEN2 Pro123Leu mutation in a Chinese Han family of Alzheimer's disease. Neurobiol Aging. 2015; 36(12):3334.e13-3334.e18. DOI: 10.1016/j.neurobiolaging.2015.09.003. View

5.
Piscopo P, Talarico G, Crestini A, Gasparini M, Malvezzi-Campeggi L, Piacentini E . A novel mutation in the predicted TMIII domain of the PSEN2 gene in an Italian pedigree with atypical Alzheimer's disease. J Alzheimers Dis. 2010; 20(1):43-7. DOI: 10.3233/JAD-2010-1369. View